

Josuel Ora
Curriculum Vitae

Part I – General Information

Full Name	Josuel Ora
Date of Birth	April 15th 1978
Place of Birth	Rome
Citizenship	Italian
Permanent Address	
Mobile Phone Number	
E-mail	josuel78@gmail.com ;
Spoken Languages	Italian and English

Part II – Education

Type	Year	Institution	Notes (Degree, Experience,...)
University graduation	2003	“Sapienza” University of Rome	Medical Degree with full marks (“110/110 et laude)
Licensure: medical licence	2003		Provincial register of Rome, position n° 52902
Specialty	2008	“Sapienza” University of Rome	Internal Medicine with full marks (70/70 et laude).
Post-doctoral Fellowship	2009	Queen’s University, Kingston, Canada	Exercise testing in Respiratory Investigation Unit, directed by Prof. Denis E. O’Donnell
Specialty	2008	“Sapienza” University of Rome	Internal Medicine with full marks (70/70 et laude).
II level Master degree	2019	“Niccolò Cusano” University of Rome	“Management sanitario”
Licensure: National Scientific License (ASN)	2021	Assistant Professor (II Level) 06/D1, SSD MED 10	Call D.D. 2175/2018 Cardiovascular Diseases and Respiratory Diseases
Licensure: National Scientific License (ASN)	2021	Assistant Professor (II Level) 06/B1, SSD MED 09	Call D.D. 2175/2018 Internal Medicine
Eligibility for UOC Head of Pneumology and Telemedicine	2021	Hospital of Rieti	G.U.R.I. n. 99 of 22/12/2020

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
2018	To present	Catholic University “Nostra Signora del Buon Consiglio”, Tirana, Albany	Professor of Respiratory Diseases for the Degree Course of Physiotherapy of the Faculty of Medicine and Surgery
2020	To present	Catholic University “Nostra Signora del Buon Consiglio”, Tirana, Albany	Professor of Respiratory Diseases for the Master's Degree in Rehabilitation Sciences of Health Professions of the Faculty of Medicine and Surgery
2016	To present	“Tor Vergata” University of Rome	Lecturer as an expert in the subject Diseases of the Respiratory System at the School of Specialization of “Diseases of the Respiratory System”
2016	To present	“Tor Vergata” University of Rome	Adjunct Professor of “Lung Diseases” at The Medicine And Surgery Course – Faculty of Medicine (English course)
2016	To present	“Tor Vergata” University of Rome	Lecturer as an expert of “Lung Diseases” at the Medicine And Surgery Course – Faculty of Medicine (Italian course)
2020	To present	“Tor Vergata” University of Rome	Adjunct Professor for “Respiratory Pathophysiology Techniques (basic and advanced)”, and “Cardiopulmonary stress test, Blood gas analysis – gas exchange” and Didactic Coordinator of the Master at the I level Master in Respiratory Pathophysiology Techniques

IIIB – Other Appointments

Start	End	Institution	Position
2020	To present	“BMC Pulmonary Medicine” journal	Associate Editor
2020	To present	Rassegna di Patologia dell’Apparato Respiratorio” journal	Associate Editor

Part IV – Teaching experience

Year	Institution	Lecture/Course
2017	Scuola Medica Ospedaliera (SMO)	Interdisciplinary course on acid-base balance, hydroelectrolytic and gas exchanges in critical ill patient
2016	Scuola Medica Ospedaliera (SMO)	Interdisciplinary course on acid-base balance, hydroelectrolytic and gas exchanges in critical ill patient
2015	Scuola Medica Ospedaliera (SMO)	Course on acute and chronic respiratory failure
2014	Scuola Medica Ospedaliera (SMO)	Practical and theoretical course in respiratory medicine
2016	Società Italiana di Pneumologia dello Sport (SIPS)	Asthma, COPD and Exercise
	Associazione Italiana di Pneumologia Ospedaliera (AIPO)	Speaker at National and Regional Congresses
2010	European Respiratory Society (ERS)	Exercise related perception

Part V - Society memberships, Awards and Honors

Year	Title
2009 to present	ERS membership
2015 to present	AIPO membership
2015 to present	Member of the AIPO Regional Executive board
2018 to present	Coordinator of the AIPO Group of Respiratory Pathophysiology

Part VI - Funding Information Study as investigator

Year	Title	Sponsor
2015	Studio SAT. BI 1237.51, R.S. 138/15 SAT - SATisfaction and adherence to COPD treatment SAT-COPD Italian observational study	Boehringer Ingelheim
2016	Studio Pearl. PT010005 R.S. 1/16, 2014-005671-92, A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)	Pearl Therapeutics AstraZeneca
2017	GSK-COPD 201038, R.S. 14/17 Studio osservazionale per quantificare incidenza e sicurezza comparativa in pazienti affetti da malattia cronica ostruttiva polmonare con associazione UMEC/VI o UMEC	GlaxoSmithKline
2017	GSK2269557, Eu 2017-001074-42 - Studio 200879 Sperimentazione clinica con GSK2269557. A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed with an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)	GlaxoSmith Kline
2018	Studio ICSLIFE. AIFA-2016-0236495, Eu 2018-000739, Studio AIFA-ISC SLIFE-0001 Comparison on 1 year treatment with inhaled bronchodilators (LABD) plus inhaled glucocorticosteroids (ICS) versus	AIFA

	LABD without ICS on rehospitalizations and/or death in elderly patients with COPD recently hospitalized because of an acute exacerbation of COPD (ICSLIFE)	
2019	Studio Tritrial - DFIDM-1802, R.S. 131/19, TRITRIAL - DFIDM-1802, Exom Group	Chiesi
2018	Studio Boreas . BOREAS/EFC15804, Eu2018-00193-28; BOREAS/EFC15804 - Dupilumab	Sanofi/Covance
Under approval	Studio Kalos . D5982C00007 - KALOS, Eu 2020-001520-34; KALOS	AstraZeneca
2020	Studio MEDEAS - EU: 2020-006054-43 MEDEAS CV-19 pneumonia	Università Degli Studi Di Trieste

Part VII – Research Activities

Keywords	Brief Description
Exercise test	the main focus of the research is based on the study of the physiopathology at rest and under stress, using the cardiopulmonary exercise test in healthy people and in diseases.
dyspnea	a specific area of research is on the causes of dyspnea through the study of respiratory mechanics and qualities of dyspnea
Respiratory mechanics	another area of research is the study of respiratory mechanics which was carried out through the cardiopulmonary stress test, the use of gastric and esophageal catheters for the evaluation of pressures
Bronchodilators	another area of research is the study of bronchodilators both from a pharmacological point of view and from translational medicine from the ex vivo model of the bronchi to patients
COPD	the most studied pathology is COPD which has been addressed both from a pathophysiological point of view at rest and under exertion and from a therapeutic point of view, underlining the positive effects of drugs in exercise tolerance and dyspnea

List of all Publications

- [1] Rogliani P, Ritondo BL, Cavalli F, et al. Synergy across the drugs approved for the treatment of asthma. *Minerva Med.* 2021;
- [2] Rogliani P, Ora J, Girolami A, et al. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. *Pulm Pharmacol Ther.* 2021;69:102050.
- [3] Ora J, Rogliani P, Dauri M, et al. Happy hypoxemia, or blunted ventilation? *Respir Res.* 2021;22:4.

- [4] **Ora J**, Prendi E, Ritondo BL, et al. Pulmonary Rehabilitation in Noncystic Fibrosis Bronchiectasis. *Respiration* [Internet]. 2021 [cited 2021 Aug 16];1–9. Available from: <https://www.karger.com/Article/FullText/517527>.
- [5] **Ora J**, Coppola A, Perduno A, et al. Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. *Monaldi Arch Chest Dis*. 2021;
- [6] **Ora J**, Calzetta L, Ritondo BL, et al. Current long-acting muscarinic antagonists for the treatment of asthma. *Expert Opin Pharmacother*. 2021;1–15.
- [7] Matera MG, **Ora J**, Cavalli F, et al. New Avenues for Phosphodiesterase Inhibitors in Asthma. *J Exp Pharmacol*. 2021;13:291–302.
- [8] Matera MG, **Ora J**, Calzetta L, et al. Sex differences in COPD management. *Expert Rev Clin Pharmacol*. 2021;14:323–332.
- [9] Matera MG, Calzetta L, **Ora J**, et al. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. *Expert Opin Drug Deliv*. 2021;18:891–906.
- [10] Liguori C, Pierantozzi M, Spanetta M, et al. Depressive and anxiety symptoms in patients with SARS-CoV2 infection. *J Affect Disord*. 2021;278:339–340.
- [11] Cazzola M, Rogliani P, Salvi SS, et al. Use of Thiols in the Treatment of COVID-19: Current Evidence. *Lung* [Internet]. 2021 [cited 2021 Sep 5];199:335–343. Available from: <https://link.springer.com/10.1007/s00408-021-00465-3>.
- [12] Cazzola M, **Ora J**, Cavalli F, et al. Treatable Mechanisms in Asthma. *Mol Diagn Ther*. 2021;25:111–121.
- [13] Cazzola M, **Ora J**, Cavalli F, et al. An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease. *BTT* [Internet]. 2021 [cited 2021 Sep 5];Volume 15:363–374. Available from: <https://www.dovepress.com/an-overview-of-the-safety-and-efficacy-of-monoclonal-antibodies-for-th-peer-reviewed-fulltext-article-BTT>.
- [14] Cazzola M, **Ora J**, Bianco A, et al. Management of COPD patients during COVID: difficulties and experiences. *Expert Rev Respir Med*. 2021;15:1025–1033.
- [15] Cazzola M, **Ora J**, Bianco A, et al. Guidance on nebulization during the current COVID-19 pandemic. *Respir Med*. 2021;176:106236.
- [16] Cazzola M, Matera MG, Rogliani P, et al. Step-up and step-down approaches in the treatment of asthma. *Expert Rev Respir Med*. 2021;15:1159–1168.
- [17] Rogliani P, Ritondo BL, **Ora J**, et al. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. *Eur Respir J*. 2020;56.
- [18] **Ora J**, Puxeddu E, Cavalli F, et al. Does bronchoscopy help the diagnosis in COVID-19 infection? *Eur Respir J*. 2020;56.
- [19] **Ora J**, Liguori C, Puxeddu E, et al. Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. *Neurol Sci*. 2020;41:2671–2674.

- [20] **Ora J**, Coppola A, Cazzola M, et al. Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease. *J Exp Pharmacol*. 2020;12:559–574.
- [21] **Ora J**, Calzetta L, Matera MG, et al. Advances with glucocorticoids in the treatment of asthma: state of the art. *Expert Opin Pharmacother*. 2020;1–12.
- [22] Liguori C, Pierantozzi M, Spanetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. *Brain Behav Immun*. 2020;88:11–16.
- [23] Liguori C, Pierantozzi M, Spanetta M, et al. Depressive and anxiety symptoms in patients with SARS-CoV2 infection. *J Affect Disord*. 2020;278:339–340.
- [24] Cazzola M, **Ora J**, Bianco A, et al. Guidance on nebulization during the current COVID-19 pandemic. *Respir Med*. 2020;176:106236.
- [25] Rogliani P, Calzetta L, **Ora J**, et al. Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis. *Multidiscip Respir Med*. 2019;14:25.
- [26] Rogliani P, Calzetta L, Matera MG, et al. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2019;20:737–750.
- [27] Cazzola M, Puxeddu E, **Ora J**, et al. Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. *Mol Diagn Ther*. 2019;23:603–614.
- [28] Rogliani P, **Ora J**, Puxeddu E, et al. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. *Pulm Pharmacol Ther*. 2018;49:20–26.
- [29] Rogliani P, **Ora J**, Matera MG, et al. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. *Expert Opin Drug Saf*. 2018;17:589–596.
- [30] Rogliani P, **Ora J**, Di Daniele N, et al. Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. *Curr Opin Pharmacol*. 2018;40:34–38.
- [31] Matera MG, Rogliani P, **Ora J**, et al. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. *Expert Opin Pharmacother*. 2018;19:2043–2053.
- [32] Faverio P, De Giacomi F, Sardella L, et al. Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. *BMC Pulm Med*. 2018;18:70.
- [33] Cazzola M, Rogliani P, Puxeddu E, et al. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? *Expert Rev Respir Med*. 2018;12:43–54.
- [34] Walsh SLF, Maher TM, Kolb M, et al. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *Eur Respir J*. 2017;50.
- [35] Rogliani P, **Ora J**, Puxeddu E, et al. Adherence to COPD treatment: Myth and reality. *Respir Med*. 2017;129:117–123.

- [36] Rogliani P, Matera MG, **Ora J**, et al. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. *Int J Chron Obstruct Pulmon Dis*. 2017;12:3469–3485.
- [37] Rogliani P, Calzetta L, Coppola A, et al. Optimizing drug delivery in COPD: The role of inhaler devices. *Respir Med*. 2017;124:6–14.
- [38] Cazzola M, **Ora J**, Rogliani P, et al. Role of muscarinic antagonists in asthma therapy. *Expert Rev Respir Med*. 2017;11:239–253.
- [39] Calzetta L, Rogliani P, **Ora J**, et al. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. *Eur Respir Rev*. 2017;26.
- [40] Calzetta L, **Ora J**, Cavalli F, et al. Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. *Respir Med*. 2017;129:189–198.
- [41] Braido F, Baiardini I, Alleri P, et al. Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. *Pulm Pharmacol Ther*. 2017;44:83–87.
- [42] Rogliani P, Puxeddu E, Ciapriani C, et al. The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. *Biomed Res Int*. 2016;2016:4547953.
- [43] Rogliani P, **Ora J**, Puxeddu E, et al. Airflow obstruction: is it asthma or is it COPD? *Int J Chron Obstruct Pulmon Dis*. 2016;11:3007–3013.
- [44] Liccardi G, Salzillo A, Calzetta L, et al. Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link? *Respirology*. 2016;21:1496–1497.
- [45] Liccardi G, Salzillo A, Calzetta L, et al. Dog allergen immunotherapy and allergy to furry animals. *Ann Allergy Asthma Immunol*. 2016;116:590.
- [46] Liccardi G, Salzillo A, Calzetta L, et al. Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? *J Allergy Clin Immunol Pract*. 2016;4:791–793.
- [47] Faisal A, Alghamdi BJ, Ciavaglia CE, et al. Common Mechanisms of Dyspnea in Chronic Interstitial and Obstructive Lung Disorders. *Am J Respir Crit Care Med*. 2016;193:299–309.
- [48] Cazzola M, Rogliani P, **Ora J**, et al. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. *Expert Opin Pharmacother*. 2016;17:977–988.
- [49] Cazzola M, Rinaldi B, Lucà G, et al. Olodaterol for the treatment of asthma. *Expert Opin Investig Drugs*. 2016;25:861–866.
- [50] Cazzola M, **Ora J**, Puxeddu E. Dual bronchodilation and exacerbations of COPD. *J Thorac Dis*. 2016;8:2383–2386.
- [51] Cazzola M, **Ora J**, Di Paolo A, et al. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD. *Pulm Pharmacol Ther*. 2016;39:48–53.

- [52] Cazzola M, Calzetta L, Puxeddu E, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. *Respir Res.* 2016;17:70.
- [53] Rogliani P, Calzetta L, **Ora J**, et al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. *Eur J Pharmacol.* 2015;761:383–390.
- [54] Rogliani P, Calzetta L, **Ora J**, et al. Canakinumab for the treatment of chronic obstructive pulmonary disease. *Pulm Pharmacol Ther.* 2015;31:15–27.
- [55] Matera MG, **Ora J**, Cazzola M. Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol. *Ther Clin Risk Manag.* 2015;11:1805–1811.
- [56] Cazzola M, Rogliani P, **Ora J**, et al. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. *Expert Rev Clin Pharmacol.* 2015;8:529–539.
- [57] Cazzola M, Calzetta L, **Ora J**, et al. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. *Respir Med.* 2015;109:1305–1311.
- [58] Rogliani P, **Ora J**, Ciapriani C, et al. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. *Respir Med.* 2014;108:307–313.
- [59] Ciavaglia CE, Guenette JA, **Ora J**, et al. Does exercise test modality influence dyspnoea perception in obese patients with COPD? *Eur Respir J.* 2014;43:1621–1630.
- [60] **Ora J**, Calzetta L, Pezzuto G, et al. A 6MWT index to predict O₂ flow correcting exercise induced SpO₂ desaturation in ILD. *Respiratory Medicine [Internet].* 2013 [cited 2020 Oct 20];107:2014–2021. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0954611113004125>.
- [61] Fiorentini A, **Ora J**, Tubani L. Autonomic system modification in Zen practitioners. *Indian J Med Sci.* 2013;67:161–167.
- [62] Cazzola M, Segreti A, Stirpe E, et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. *Respiratory Medicine [Internet].* 2013 [cited 2020 Oct 20];107:107–111. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0954611112003630>.
- [63] **Ora J**, Laveneziana P, Wadell K, et al. Effect of obesity on respiratory mechanics during rest and exercise in COPD. *J Appl Physiol (1985).* 2011;111:10–19.
- [64] Laveneziana P, Webb KA, **Ora J**, et al. Evolution of Dyspnea during Exercise in Chronic Obstructive Pulmonary Disease: Impact of Critical Volume Constraints. *Am J Respir Crit Care Med [Internet].* 2011 [cited 2020 Oct 20];184:1367–1373. Available from: <http://www.atsjournals.org/doi/abs/10.1164/rccm.201106-1128OC>.
- [65] Aliverti A, Kayser B, Lo Mauro A, et al. Respiratory and leg muscles perceived exertion during exercise at altitude. *Respir Physiol Neurobiol.* 2011;177:162–168.
- [66] **Ora J**, Jensen D, O'Donnell DE. Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches. *Curr Opin Pulm Med.* 2010;16:144–149.

- [67] Deesomchok A, Fisher T, Webb KA, et al. Effects of obesity on perceptual and mechanical responses to bronchoconstriction in asthma. *Am J Respir Crit Care Med*. 2010;181:125–133.
- [68] **Ora J**, Laveneziana P, Ofir D, et al. Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. *Am J Respir Crit Care Med*. 2009;180:964–971.
- [69] O'Donnell DE, **Ora J**, Webb KA, et al. Mechanisms of activity-related dyspnea in pulmonary diseases. *Respir Physiol Neurobiol*. 2009;167:116–132.
- [70] O'Donnell DE, Laveneziana P, **Ora J**, et al. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. *Thorax*. 2009;64:216–223.
- [71] Laveneziana P, Palange P, **Ora J**, et al. Bronchodilator effect on ventilatory, pulmonary gas exchange, and heart rate kinetics during high-intensity exercise in COPD. *Eur J Appl Physiol*. 2009;107:633–643.
- [72] Onorati P, Martolini D, **Ora J**, et al. Estimation of the exercise ventilatory compensation point by the analysis of the relationship between minute ventilation and heart rate. *Eur J Appl Physiol*. 2008;104:87–94.
- [73] Perciaccante A, Fiorentini A, **Ora J**, et al. A case of pancytopenia and splenomegaly: haematological disease? *Intern Emerg Med*. 2007;2:238–242.

Signature

A handwritten signature in black ink that reads "Josuel Ora". The signature is written in a cursive style with a large, stylized initial 'J'.